Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Rogaine marketing exclusivity challenged in petition to FDA from D.C. law firm.

This article was originally published in The Tan Sheet

Executive Summary

OTC ROGAINE THREE-YEAR MARKET EXCLUSIVITY CONTESTED by Washington, D.C. law firm Hyman, Phelps & McNamara in a Jan. 18 petition submitted to FDA. Filed on behalf of an unnamed client "that intends to market minoxidil for the treatment of baldness," the petition maintains that the data presented by Pharmacia & Upjohn in support of its Rx-to-OTC switch application fails to include "any new and essential clinical investigation."
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel